Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

References

• Centers for Disease Control and Prevention (CDC). Monitoring selected National HIV prevention and care objectives by using HIV Surveillance Data—United States and 6 Dependent Areas—2011. HIV Surveillance Supplemental Report 2013;18(No. 5). Atlanta, GA: CDC, 2013. http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed April 15, 2015
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Diagnoses of HIV Infection in the United States and dependent areas, 2013. HIV Surveillance Report, 2013; vol. 25. Atlanta, GA: CDC, 2015. http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed April 15, 2015
   Google Scholar
• Centers for Disease Control and Prevention (CDC). CDC fact sheet: new HIV infections in the US 2007-2010. Atlanta, GA: CDC, 2013. http://www.cdc.gov/hiv/basics/statistics.html. Accessed August 9, 2013
   Google Scholar
• Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care 2015;53:293-301
   PubMed Web of Science ®Google Scholar
• The Henry J. Kaiser Family Foundation. Quick Take: an update on the ACA & HIV: Medicaid Health Homes. Menlo Park, CA, 2012. http://kff.org/health-reform/fact-sheet/quick-take-an-update-on-the-aca/. Accessed June 2, 2014
   Google Scholar
• FDA. FDA approval of Atripla, 3-drug fixed dose combination antiretroviral. Silver Spring, MD: US Food and Drug Administration, 2006. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124444.htm. Accessed August 20, 2013
   Google Scholar
• Department of Health and Human Services. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected adults and adolescents: Panel on Antiretroviral Guidelines for Adults and Adolescents. Rockville, MD: Department of Health and Human Services, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed June 2, 2014
   Google Scholar
• FDA. FDA approves new drug (Tivicay [dolutegravir]) to treat HIV infection. Silver Spring, MD: US Food and Drug Administration, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Accessed February 20, 2014
   Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369:1807-18
   PubMed Web of Science ®Google Scholar
• Walmsey S, Berenguer J, Khuong-Josses M, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE Study (ING114467) Conference on Retroviruses and Opportunistic Infections (CROI) 2014. Boston, MA; 2014
   Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35
   PubMed Web of Science ®Google Scholar
• Patel DA, Snedecor SJ, Tang WY, et al. 48-week efficacy of dolutegravir relative to commonly used 3rd agents in treatment-naïve HIV-1-Infected patients: a systematic review and network meta-analysis. 14th European AIDS Conference Brussels, Belgium 2013
   Google Scholar
• Gold M, Siegel J, Russell L, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996
   Google Scholar
• Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312:410-25
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63:77-85
   PubMed Web of Science ®Google Scholar
• Jansen K, Sonnerborg A, Brockmeyer N, et al. Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses 2013;29:564-73
   PubMed Web of Science ®Google Scholar
• Svedhem-Johansson V, Pugliese P, Brockmeyer NH, et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res 2013;11:333-41
   PubMed Web of Science ®Google Scholar
• Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14:859-64
   PubMed Web of Science ®Google Scholar
• Banhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res 2012;10:171-81
   PubMed Web of Science ®Google Scholar
• Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996–2002). Int J STD AIDS 2008;19:297-304
   PubMed Web of Science ®Google Scholar
• Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr 2012;59:489-93
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62
   PubMed Web of Science ®Google Scholar
• Anude CJ, Eze E, Onyegbutulem HC, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis 2013;13:113
   PubMed Web of Science ®Google Scholar
• Simpson KN, Pei PP, Moller J, et al. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics 2013;31:427-44
   PubMed Web of Science ®Google Scholar
• Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011;25:1289-98
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013;27:973-9
   PubMed Web of Science ®Google Scholar
• Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009;23:1743-53
   PubMed Web of Science ®Google Scholar
• Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health 2008;11:1144-53
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. RED BOOK Online® via MicroMedex Gateway. New York, NY: Truven Health Analytics, 2013. http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/D1626C/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/86DBB2/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/pf.Logout. Accessed February 20, 2014
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-8
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Justice AC, Alexander GC, et al. Adherence and HIV RNA suppression in the current Era of Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr 2015;69:493-8
   PubMedGoogle Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63:96-100
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg mail RS, et al. Closing the Gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013;8:e81355
   PubMed Web of Science ®Google Scholar
• Juday T, Correll T, Anene A, et al. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US. Clinicoecon Outcomes Res 2013;5:437-45
   PubMedGoogle Scholar
• Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States. Value Health 2011;14:657-64
   PubMed Web of Science ®Google Scholar